Did You Know...
...In 1790, the cost to obtain a patent was between $4 and $5.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8188041 | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents The invention features a method of treating an inflammatory condition in an individual, comprising administering an agent inhibits the interaction between a Toll-like receptor 2 (TLR2) and a high mobility group B (HMGB) polypeptide to the individual. The invention a... | 05/29/2012 |
| 8183210 | Reconstituted surfactants having improved properties Reconstituted surfactants comprising a lipid carrier, a polypeptide analog of the native surfactant protein SP-C, and a polypeptide analog of the native surfactant protein SP-B are useful for the treatment and/or prophylaxis of RDS and other respiratory disorders. | 05/22/2012 |
| 8168592 | CGRP peptide antagonists and conjugates Disclosed is a composition of matter that involves a CGRP peptide antagonist. A pharmaceutical composition is disclosed that comprises the composition of matter and a pharmaceutically acceptable carrier, which can be configured for administration to a patient. Also ... | 05/01/2012 |
| 8148328 | Salicylanilides enhance oral delivery of therapeutic peptides This invention pertains to the surprising discovery that salicylanilides, e.g., niclosamide and/or niclosamide analogues when orally administered in conjunction with a peptide pharmaceutical (e.g., a class A amphipathic helical peptide as described herein) significa... | 04/03/2012 |
| 8124586 | Prevention and reduction of blood loss Methods are described for preventing or reducing ischemia and/or systemic inflammatory response in a patient such as perioperative blood loss and/or systemic inflammatory response in a patient subjected to cardiothoracic surgery, e.g. coronary artery bypass grafting... | 02/28/2012 |
| 8110548 | Method for treating cartilage disorders The present invention relates to a method for the treatment of a cartilage disorder, including cartilage damaged by injury or degenerative cartilagenous disorders. The method involves contacting the cartilage with an IGF-1 analog with altered affinity for IGF-bindin... | 02/07/2012 |
| 8071546 | Uses of pegylated albumin The present invention is directed to uses of PEGylated albumins which include methods of treating reduced functional capillary density, reduced blood volume, septic shock and cardiac arrhythmia in a subject, which comprise administering to the subject a therapeutica... | 12/06/2011 |
| 8071545 | Therapies and compositions for controlling the stress mechanism and for stabilizing hemostasis in an organism A method for treating skin malignancies, malignant tumors, metastatic malignancies and abnormal skin growths in an organism by treating the organism to inhibit the stress mechanism via different pathways and synergistically reduce the production of thrombin in the o... | 12/06/2011 |
| 8063018 | Bivalent thrombin binding molecules comprising linkers There is provided herein a multivalent binding molecule and uses thereof. The molecule is useful in binding a target under certain conditions and releasing it under other conditions. The molecule has the general formula (1) of BM1-L-(BM2)n (1) wherein, BM... | 11/22/2011 |
| 8063019 | Scaffold polypeptides for heterologous peptide display The present invention relates to the use of Stefin A as a scaffold protein for the display of inserted peptides, particularly wherein the Stefin A is a human Stefin A. Several mutations are advantageously made in the wild type stefin A sequence to improve it as a sc... | 11/22/2011 |
| 8053410 | Pegylated factor VII glycoforms The invention concerns a preparation comprising a plurality of Factor VII polypeptides or Factor VII-related polypeptides, wherein the polypeptides comprise asparagine-linked and/or serine-linked oligosaccharide chains, and wherein at least one oligosaccharide group... | 11/08/2011 |
| 8039436 | Mutated HOXB4 proteins with improved stability, and methods of use thereof A polypeptide, the amino acid sequence of which comprises a sequence as set forth in SEQ ID NO:2, including at least one mutation within the degron domain of the polypeptide encompassed between positions 1 and 35 of the sequence, wherein said at least one mutation r... | 10/18/2011 |
| 8034771 | IL-1F6 polypeptides The present invention provides compositions and methods relating to IL-1Rrp2 requiring proteins. ... | 10/11/2011 |
| 8034775 | Kallikrein-inhibitor therapies Methods are described for preventing or reducing ischemia, e.g., cerebral ischemia, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia, in a patient. ... | 10/11/2011 |
| 8030276 | Treating cardiovascular disease with TRPC3 channel protein The invention refers to the use of a TRPC channel, an inactivating mutant thereof, or a nucleotide sequence coding for the TRPC channel or for the inactivating mutant for the production of a medicament for the treatment of a cardiovascular disease and a method of sc... | 10/04/2011 |
| 8026214 | Liquid, aqueous pharmaceutical compositions of factor VII polypeptides The present invention is directed to liquid, aqueous pharmaceutical compositions stabilised against chemical and/or physical degradation containing Factor VII polypeptides, and methods for preparing and using such compositions, as well as vials containing such compo... | 09/27/2011 |
| 8022031 | Liquid composition of factor VII polypeptides A liquid aqueous composition comprising (i) a factor VII polypeptide, (ii) an agent suitable for keeping pH in the range of from about 4.0 to about 8.0; (iii) an agent selected from the list of: a calcium salt, a magnesium salt, or a mixture thereof; wherein the con... | 09/20/2011 |
| 8012933 | Use of the cathelicidin LL-37 and derivatives therof for wound healing Use of the antimicrobial cathelicidin peptide II-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithelial and stromal cells and thereby healing of wounds, such as chron... | 09/06/2011 |
| 8008256 | Combination therapy for treatment of cancer The invention relates to compositions and methods for treating diseases. In particular aspects, the invention relates to administering a combination of a disintegrin with a microtubule stabilizing agent useful for treatment of cancer. ... | 08/30/2011 |
| 7998931 | Vascular endothelial cell growth factor antagonists and uses thereof The present invention provides vascular endothelial cell growth factor (VEGF) antagonists and methods of using VEGF antagonists. VEGF antagonists contemplated by the invention include VEGF antibodies and VEGF receptor fusion proteins. Methods of treating edema and s... | 08/16/2011 |
| 7977312 | Compositions and methods for increasing bone mineralization A novel class or family of TGF-β binding proteins is disclosed. Also disclosed are assays for selecting molecules for increasing bone mineralization and methods for utilizing such molecules. ... | 07/12/2011 |
| 7973010 | Full length polynucleotide coding chicken type II collagen and the use of it The present invention relates to a nucleic acid molecule as set forth in SEQ ID NO:1 comprising a polynucleotide sequence encoding full length chicken type II collagen (CCII), or a fragment thereof in possession of the same biological functions as well as CCII encod... | 07/05/2011 |
| 7964564 | Chimeric natriuretic peptides Peptides of Dendroaspis, including chimeric peptides thereof, are provided, as well as methods of using the peptides as natriuretics, diuretics, and/or vasodilators. ... | 06/21/2011 |
| 7960344 | Methods of enhancing functioning of the large intestine The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the large intestine. In particular, it has now been demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue o... | 06/14/2011 |
| 7956036 | Polypeptide and DNA thereof useful as a neovascular marker A marker for neovascularization, vascular disease, inflammatory disease, entoptic neovascular disease, reproductive system disease, central nervous system disease and cancer, the method of detection of the marker and a diagnosis kit of the diseases are provided. Add... | 06/07/2011 |
| 7956035 | Treatment of endothelial dysfunction in diabetic patients A method for the treatment of endothelial dysfunction in a diabetic patient, including both diabetes induced macrovascular disorders and diabetes induced microvascular disorders, comprises administration, preferably parenteral administration, to the patient of an ef... | 06/07/2011 |
| 7951776 | Methods for treatment of type 1 diabetes The present invention relates generally to the identification of biological markers associated with an increased risk of developing Diabetes, as well as methods of using such biological markers in diagnosis and prognosis of Diabetes. The biological markers of the in... | 05/31/2011 |
| 7947650 | Article of manufacture The present invention relates to a method for the treatment of a cartilage disorder, including cartilage damaged by injury or degenerative cartilagenous disorders. The method involves contacting the cartilage with an IGF-1 analog with altered affinity for IGF-bindin... | 05/24/2011 |
| 7939496 | Modified human growth horomone polypeptides and their uses Modified growth hormone polypeptide and uses thereof are provided. ... | 05/10/2011 |
| 7932227 | Lacritin-syndecan fusion proteins The present invention relates to methods and compositions useful for the regulation of lacritin, syndecan, and lacritin-syndecan interactions and the signaling pathway downstream of lacritin-syndecan interactions. The invention also relates to regulating lacritin-sy... | 04/26/2011 |
| 7932226 | NFκB transcriptional activity inhibitory agent and anti-inflammatory agent and a steroid action enhancing agent It is intended to surely and effectively inhibit the transcriptional activity of NFκB and to obtain a more effective anti-inflammatory effect. Further, it is intended to obtain an equivalent effect even if the amount used of a steroid agent is reduced. An ag... | 04/26/2011 |
| 7928065 | Methods of treatment using exendin peptides or GLP-1 peptides Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed.... | 04/19/2011 |
| 7928064 | Transgenically produced antithrombin III This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GalNAc) along with fucose, N-acety... | 04/19/2011 |
| 7919461 | Erythropoietin receptor peptide formulations and uses The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell pr... | 04/05/2011 |
| 7919463 | Growth-stimulating polypeptides for use in fish and crustaceans The present invention is related to polypeptides derived from tilapia growth hormone. ... | 04/05/2011 |
| 7919462 | Inhibitors of human plasmin derived from the Kunitz domains This invention features novel proteins that are homologous to the first Kunitz domain (K1) of lipoprotein-associated coagulation inhibitor (LACI), and are capable of inhibiting plasmin and nucleic acids encoding these proteins. The invention also features the use of... | 04/05/2011 |
| 7915222 | Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis The invention relates to methods and compositions for treating undifferentiated arthritis (UA) and/or preventing the development of rheumatoid arthritis (RA) in subjects with UA by administering to a subject in need thereof an effective amount of soluble CTLA4 molec... | 03/29/2011 |
| 7915221 | Methods for construction and screening of libraries of chemokine variants The present invention provides a method for the design and/or the selection of agonist or antagonist chemokine variants combining a phage display technology and a screening on living cells expressing the receptor of the corresponding native chemokine. It also provid... | 03/29/2011 |
| 7910549 | MN gene and protein Identified herein is the location of the MN protein binding site, and MN proteins/polypeptides that compete for attachment to vertebrate cells with immobilized MN protein. Such MN proteins/polypeptides prevent cell-cell adhesion and the formation of intercellular co... | 03/22/2011 |
| 7910548 | Methods for treating obesity Methods for treating obesity are disclosed which comprise administration of a therapeutically effective amount of an amylin or an amylin agonist alone or in conjunction with another obesity relief agent. ... | 03/22/2011 |
